Will a new tablet match the capsule for hot flash relief?
NCT ID NCT07762287
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study tests whether a new tablet form of elinzanetant, a medicine used to manage hot flashes linked to hormone changes, is absorbed and processed by the body in a similar way to the existing capsule. About 100 healthy women aged 18 to 65 will take both forms at different times, with blood samples measuring how the drug behaves. The goal is to see if the tablet can be a suitable alternative to the capsule.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Elinzanetant (BAY 3427080) in two oral formulations: a new tablet and an existing capsule
- What this could lead to
- If the tablet is absorbed similarly to the capsule, it could offer a more convenient or cost-effective way to deliver this medicine for managing hot flashes.
- What could go wrong
- This is an early-stage study in healthy volunteers, not patients, so results may not predict real-world effectiveness. The tablet might not match the capsule's absorption, and side effects are still being assessed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASOMOTOR SYMPTOMS AS A SEX HORMONE-DEPENDENT DISORDER IN WOMEN are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences
RECRUITINGMount Royal, Quebec, H3P 3P1, Canada